Search
Vivos Therapeutics Inc
VVOSAdd to Watchlist
0.428USD
-0.072-14.48%
Close 06/22, 16:00（ET）Quotes delayed by 15 min
3.97MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-22The current earnings forecast score of Vivos Therapeutics Inc is 7.33, ranking 142 out of 203 in the Healthcare Equipment & Supplies industry. The average price target is 5.50, with a high of 7.00 and a low of 4.00.
Analyst Rating
Based on
3
analysts
Buy
Current Rating
2.450
Target Price
+390.00%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
117
Total
6
Median
9
Average
Company name
Ratings
Analysts
Vivos Therapeutics Inc
VVOS
3
Medtronic PLC
MDT
34
Dexcom Inc
DXCM
32
Stryker Corp
SYK
32
Zimmer Biomet Holdings Inc
ZBH
31
Abbott Laboratories
ABT
30
1
2
3
...
24
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Vivos Therapeutics Inc's expected revenue for the next quarter?
Vivos Therapeutics Inc's expected revenue is 5.49M.
What is Vivos Therapeutics Inc's price target?
Analysts forecast that Vivos Therapeutics Inc's price target is USD 5.50, with the highest forecast at USD 7.00 and the lowest forecast at USD 4.00.
How have Vivos Therapeutics IncVVOS's recent earnings per share performed?
The market expectation was USD -0.52, while Vivos Therapeutics IncVVOS's earnings per share (EPS) for the previous quarter was USD -0.55. EPS for the next quarter is expected at USD -0.31.
What is the analyst rating for Vivos Therapeutics Inc?
Based on the ratings of Vivos Therapeutics Inc's stock from 3 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
